Skip to main content
SpringerLink
Log in

Regional Therapy in Ovarian Cancer

  • Chapter
Regional Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 971 Accesses

Abstract

Advanced epithelial ovarian cancer (EOC) is an aggressive disease that remains and progresses inside the peritoneal cavity for most of its natural history. Despite the initial relative sensibility to first-line chemotherapy, most patients relapse and ultimately die of chemoresistant disease. The best second treatment option for recurrent disease has not been defined thus far. Secondary cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy (HIPEC) seems to constitute a possible second-line treatment option based on the results of phase II studies. A prospective randomized study testing the effectiveness of CRS + HIPEC in EOC is ongoing and the future prospects should aim at the refinement of its indications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McGuire WP, Hoskin WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1–6.

    Article  PubMed  CAS  Google Scholar 

  2. Conte PF, Gadducci A, Cianci C. Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 2001;11(Suppl 1):52–56.

    Article  PubMed  Google Scholar 

  3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: 1248–1259.

    Article  PubMed  Google Scholar 

  4. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–166.

    Article  PubMed  CAS  Google Scholar 

  5. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery Is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: prospective study. Gynecol Oncol 1998;69:103–108.

    Article  PubMed  CAS  Google Scholar 

  6. Heintz APM, van Oostrom AT, Trimbos JBMC, et al. The treatment of advanced ovarian carcinoma. I. Clinical variables associated with prognosis. Gynecol Oncol 1988;30:348–358.

    Google Scholar 

  7. Le T, Krepart GV, Lotocki RJ, Heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma. Gynecol Oncol 1997;67:208–214.

    Article  PubMed  CAS  Google Scholar 

  8. Bertelson K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990;38:203–209.

    Article  Google Scholar 

  9. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH Wang HW. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203–209.

    Article  PubMed  CAS  Google Scholar 

  10. LoCoco S, Covens A, Carney M, et al. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995;59:194–199.

    Article  PubMed  CAS  Google Scholar 

  11. Neijt JP, ten Bokkel Huinink WW, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594–600.

    Article  PubMed  CAS  Google Scholar 

  12. Michel G, De Iaco P, Castaigne D, El-Hassan MJ, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynecol Oncol 1997;18:9–15.

    CAS  Google Scholar 

  13. Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990;39:115–118.

    Article  PubMed  CAS  Google Scholar 

  14. Deppe G, Malviya VK, Boike G, Malone JM Jr. Use of Cavitron surgical aspirator for debulking of diaphragmatic metastases in patients with advanced carcinoma of the ovaries. Surg Gynecol Obstet 1989; 168:455–456.

    PubMed  CAS  Google Scholar 

  15. Rose PG. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992;166:843–846.

    PubMed  CAS  Google Scholar 

  16. Benedetti-Panici P, Maneschi F, Scambia G, Cutillo G, Greggi S, Mancuso S. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet Gynecol 1996;87:532–538.

    Article  PubMed  CAS  Google Scholar 

  17. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 2001;82:435–441.

    Article  PubMed  CAS  Google Scholar 

  18. De Gramont A, Drolet Y, Varette C, et al. Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur J Cancer Clin Oncol 1989;25:451–457.

    Article  PubMed  Google Scholar 

  19. Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards C.L, Rutledge FN. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985;5:1129–1135.

    Article  Google Scholar 

  20. Podratz KC, Schray MF, Wieand HS, et al. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988;31:9–24.

    Article  PubMed  CAS  Google Scholar 

  21. Hoskins WJ, Rubin SC, Dulaney E, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol 1989;34:365–371.

    Article  PubMed  CAS  Google Scholar 

  22. Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at secondlook laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1997;66: 171–178.

    Article  PubMed  CAS  Google Scholar 

  23. Obermaier A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 2001;80:432–436.

    Article  Google Scholar 

  24. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004;95:273–280. Review.

    Article  PubMed  CAS  Google Scholar 

  25. Salom E, Almeida Z, Mirhashemi R. Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002;14:519–527. Review.

    Article  PubMed  Google Scholar 

  26. ten Bokkel Huinink WW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183–2193.

    Google Scholar 

  27. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312–3322.

    PubMed  CAS  Google Scholar 

  28. Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, Kose K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 2005;97:74–79.

    Article  PubMed  Google Scholar 

  29. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547–555.

    Article  PubMed  CAS  Google Scholar 

  30. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.

    Article  PubMed  CAS  Google Scholar 

  31. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–1007.

    PubMed  CAS  Google Scholar 

  32. Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1999;7:83–90.

    Article  Google Scholar 

  33. Dahl O, Dalene R, Schem BC, Mella O. Status of clinical hyperthermia. Acta Oncol 1999;38:863–873.

    Article  PubMed  CAS  Google Scholar 

  34. Roca C, Primo L, Valdembri D, et al. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res. 2003;63:1500–1507. Erratum in: Cancer Res. 2003;63:2345.

    PubMed  CAS  Google Scholar 

  35. Calderwood SK, Hahn GM Thermal sensitivity and resistance of insulin-receptor binding. Biochim Biophys Acta 1983;756:1–8.

    PubMed  CAS  Google Scholar 

  36. DuBose DA, Hinkle JR, Morehouse DH, Ogle PL. Model for environmental heat damage of the blood vessel barrier. Wilderness Environ Med 1998;9:130–136.

    PubMed  CAS  Google Scholar 

  37. Xu M, Myerson RJ, Straube WL, et al. Radiosensitization of heat resistant human tumor cells by 1 hour at 41.1 degrees C and its effect on DNA repair. Int J Hyperthermia 2002; 18:385–403.

    Article  PubMed  CAS  Google Scholar 

  38. Vaupel PW. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia. Klin Padiatr 1997;209:243–249.

    Article  PubMed  CAS  Google Scholar 

  39. Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin North Am 1989;27:621–627.

    PubMed  CAS  Google Scholar 

  40. Engelhardt R. Hyperthermia and drugs. Recent Results Cancer Res 1987;104:136–203.

    PubMed  CAS  Google Scholar 

  41. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096–1099.

    PubMed  CAS  Google Scholar 

  42. Vaart PJM, Vange N, Zoetmulder FAN, et al. intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148–154.

    Article  PubMed  Google Scholar 

  43. Hettinga JVE, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatinsensitive and-resistant tumor cells. Br J Cancer 1997;75:1735–1743.

    PubMed  CAS  Google Scholar 

  44. Bull JMC. An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res 1984;44:4853s–4856s.

    PubMed  CAS  Google Scholar 

  45. Sugarbaker P.H. Peritonectomy procedures. Ann Surg 1995;221:29–42.

    Article  PubMed  CAS  Google Scholar 

  46. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996;15:49–58.

    Google Scholar 

  47. Sugarbaker PH. Laser-mode electrosurgery. Cancer Treat Res 1996;82:375–385.

    PubMed  CAS  Google Scholar 

  48. Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin North Am 2003;12:561–583.

    Article  Google Scholar 

  49. Paul H. Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer, in Peritoneal Carcinomatosis: Drugs and Diseases (Sugarbaker PH, ed.), Kluwer. Boston: 1996:75–87.

    Google Scholar 

  50. Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. In press Ann Surg Oncol 2005;12:910–918.

    Article  PubMed  Google Scholar 

  51. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–796.

    Article  PubMed  CAS  Google Scholar 

  52. Salle B., Gilly F.N., Carry P.Y., Sayag A., Brachet A., Braillon G. Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data. J Gynecol Obstet Biol Reprod (Paris) 1993;22:369–371.

    CAS  Google Scholar 

  53. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol 2004; 15:1558–1565.

    Article  PubMed  CAS  Google Scholar 

  54. Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg Oncol Clin N Am. 2003;12:561–583.

    Article  PubMed  Google Scholar 

  55. de Bree E, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103–110.

    Article  PubMed  Google Scholar 

  56. Vaart P.J.M., Vange N., Zoetmulder F.A.N., et al. intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148–154.

    Article  PubMed  Google Scholar 

  57. van der Vange N, van Goethem AR, Zoetmulder FA, et al. Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000;26:663–668.

    Article  PubMed  Google Scholar 

  58. Steller M. A., Egorin M.J., Trimble E.L., et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol 1999;43:106–114.

    Article  PubMed  CAS  Google Scholar 

  59. Nicoletto MO, Padrini R, Galeotti F, et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000;45:457–462.

    Article  PubMed  CAS  Google Scholar 

  60. Deraco M., Rossi C.R., Pennacchioli E., et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87: 120–126.

    PubMed  CAS  Google Scholar 

  61. Cohen CJ. Surgical considerations in ovarian cancer. Semin Oncol 1985; 12:53–56.

    PubMed  CAS  Google Scholar 

  62. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235–241.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy

    Marcello Deraco MD & Shigeki Kusamura MD

  2. Department of Surgery, Gynecology Unit, National Cancer Institute of Milan, Italy

    Francesco Raspagliesi MD

Authors
  1. Marcello Deraco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Raspagliesi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Kusamura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

  2. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) & Ulrike Stein PhD (Assistant Professor) (Professor and Head of Surgical Oncology) &  (Assistant Professor)

  3. Tumor Metastasis and Therapy Response Program, Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Ulrike Stein PhD (Assistant Professor) (Assistant Professor)

  4. Erasmus University MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Alexander M. M. Eggermont MD, PhD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Deraco, M., Raspagliesi, F., Kusamura, S. (2007). Regional Therapy in Ovarian Cancer. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-225-0_19

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-672-6

  • Online ISBN: 978-1-59745-225-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation